Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jul;29(7):814-816.
doi: 10.1002/pds.4899. Epub 2019 Nov 6.

Using real-world data to evaluate biosimilar switching

Sarah K Dutcher  1 , Efe Eworuke  1 , Michael D Blum  1 , Robert Ball  1
Affiliations
Comment

Using real-world data to evaluate biosimilar switching

Sarah K Dutcher et al. Pharmacoepidemiol Drug Saf. 2020 Jul.
No abstract available

PubMed Disclaimer

Comment on

Similar articles

See all similar articles

Cited by

References

REFERENCES

    1. Desai RJ, Kim SC, Curtis JR, et al. Methodologic considerations for non-interventional studies of switching from reference biologic to biosimilars. Pharmacoepidemiol Drug Saf. 2019. https://doi.org/10.1002/pds.4809
    1. Drugs@FDA: FDA approved drug products. 2019. Accessed July 11, 2019, at https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
    1. Christl LA, Woodcock J, Kozlowski S. Biosimilars: the US regulatory framework. Annu Rev Med. 2017;68(1):243-254.
    1. Dougherty MK, Zineh I, Christl L. Perspectives on the current state of the biosimilar regulatory pathway in the United States. Clin Pharmacol Ther. 2018;103(1):36-38.
    1. Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. April 2015.

LinkOut - more resources